|Bid||47.03 x 600|
|Ask||49.63 x 2300|
|Day's Range||49.33 - 49.50|
|52 Week Range||39.95 - 50.13|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.32%|
The curious metamorphoses of D. Trump: dangerous populist, a new Reagan, an eccentric Republican, and a harmless fool What the Trump rally means The dawn of a new era for international investing
GlaxoSmithKline (GSK) reported a 19.0% rise in 1Q17 revenues to ~7.4 billion pounds, driven by an operational rise of 5.0% and a favorable currency impact of 14.0%.
Thanks to Trump, most investors have been focused on the domestic equity world. But with the possible unwinding of the Trump Trade, foreign stocks have been outperforming as of late and could be interesting additions for some investors out there. Find out if the trends can continue and what the current pitfalls are for international stocks in this week's podcast!
GlaxoSmithKline’s top line increased 17% to ~27.9 billion pounds for 2016, driven by an operational increase of 6% and a favorable currency impact of ~11%.
Will emerging markets repeat performance in 2017? Emerging markets (ACWX) posted equally impressive performance in comparison to the S&P 500 index (SPX-INDEX) in 2016. The biggest advantage posed by the…...